The Critical Steps for Protein Therapeutic Potency Assay Development
Potency assays are an important part of the drug development process and are required throughout the lifetime of the product. The potency assay needs to correlate with the mechanism of action and provide an indication of stability. With these requirements comes a myriad of challenges in the development process, especially as therapeutics become increasingly complex. Assay development should be stepwise, starting with proof of concept, then optimization using Design of Experiment (DOE) to identify the best parameters quickly. Once developed, a new challenge is presented in the form of assay qualification and validation to GMP. To avoid these challenges at later stages when a delay is costly, it's crucial that the development starts early in the drug development process. The lifecycle of potency assay development ideally should be stepwise across the lifetime of the therapeutic development. Sartorius has developed their CHO platform for protein expression with this in mind and has designed the platform to include assay development services right from the start. This webinar will discuss the process of assay development, qualification, and validation for critical potency assays and how Sartorius supports customers through this vital step.
Key Learning Objectives
- What is potency and why do we need to measure it?
- What are the key considerations for developing potency assays?
- How Sartorius assay development services tackle potency assay development through case studies.
- The lifecycle of a potency assay from development to validation.
- The benefits of assay development as part of the Sartorius CHO platform.
Jennifer Lawson
Global Product Manager, Cell Banking and Testing, Sartorius
Jennifer Lawson joined Sartorius in 2015 with the acquisition of the BioOutsource organization. She currently works as the Global Product Manager for the protein therapeutics cGMP cell banking, analytical, and biosafety testing service portfolio. Jennifer gained her Ph.D. in Immunology from Kings College London, UK, before starting her career in the contract research industry, focusing on early-stage pre-clinical services.